Bruce L. Claflin's most recent trade in Idexx Laboratories, Inc. was a trade of 600 Non-Qualified Stock Option (right-to-buy) done . Disclosure was reported to the exchange on May 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 600 | 600 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 257 | 257 | - | - | Deferred Stock Unit | |
| CIENA Corp. | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2025 | 3,738 | 63,085 (0%) | 0% | 0 | Common Stock | |
| CIENA Corp. | Bruce L. Claflin | Director | Sale of securities on an exchange or to another person at price $ 84.96 per share. | 06 Jan 2025 | 16,912 | 59,347 (0%) | 0% | 85.0 | 1,436,852 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Sale of securities on an exchange or to another person at price $ 540.80 per share. | 17 May 2024 | 200 | 161 (0%) | 0% | 540.8 | 108,160 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 609 | 609 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 262 | 863 | - | - | Deferred Stock Unit | |
| CIENA Corp. | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 4,438 | 76,259 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 645 | 645 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 257 | 601 | - | - | Deferred Stock Unit | |
| CIENA Corp. | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 4,331 | 71,821 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 945 | 945 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 344 | 344 | - | - | Deferred Stock Unit | |
| CIENA Corp. | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 3,722 | 67,490 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2021 | 1,560 | 1,560 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2021 | 1,560 | 361 (0%) | 0% | 0 | Common Stock | |
| CIENA Corp. | Bruce L. Claflin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Nov 2021 | 11,136 | 63,768 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 160.28 per share. | 11 Oct 2021 | 1,921 | 1,921 (0%) | 0% | 160.3 | 307,898 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2021 | 1,921 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 723 | 723 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 224 | 2,552 | - | - | Restricted Stock Unit | |
| CIENA Corp. | Bruce L. Claflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 4,116 | 74,904 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Sale of securities on an exchange or to another person at price $ 536.89 per share. | 16 Feb 2021 | 6,745 | 586 (0%) | 0% | 536.9 | 3,621,293 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 5,902 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.00 per share. | 16 Feb 2021 | 5,902 | 6,206 (0%) | 0% | 85 | 501,670 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 1,125 | 1,921 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 160.28 per share. | 16 Feb 2021 | 1,125 | 7,331 (0%) | 0% | 160.3 | 180,315 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Sale of securities on an exchange or to another person at price $ 537.19 per share. | 16 Feb 2021 | 586 | 0 (0%) | 0% | 537.2 | 314,795 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Sale of securities on an exchange or to another person at price $ 385.11 per share. | 14 Aug 2020 | 5,629 | 304 (0%) | 0% | 385.1 | 2,167,803 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.54 per share. | 14 Aug 2020 | 5,629 | 5,933 (0%) | 0% | 70.5 | 397,070 | Common Stock |
| IDEXX Laboratories | Bruce L. Claflin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2020 | 5,629 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Bruce L. Claflin | Director | Sale of securities on an exchange or to another person at price $ 378.08 per share. | 14 Aug 2020 | 1,111 | 304 (0%) | 0% | 378.1 | 420,047 | Common Stock |